Global Plant-based
Biologics Market, by Product Type (Monoclonal Antibodies, Alpha Interferon,
Glucocerebrosidase, Vaccines, and Others), by Source Type (Carrot, Tobacco
Leaves, Rice Seeds, Alfalfa, and Others), by Disease Indication (Gaucher
Disease, Tooth Decay, Hepatitis, Lymphoma, and Others), and by Region (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is
estimated to be valued at US$ 19.4 million in 2020 and is expected to exhibit a
CAGR of 3.4% during the forecast period (2020-2027), as highlighted in a new
report published by Coherent Market Insights.
Plant-based Biologics Market -
Impact of Coronavirus (COVID-19) Pandemic
Several companies are engaged in
various activities to support hospitals, diagnostic centers, and others, in
order to combat the COVID-19 pandemic. Companies are also introducing various
products to combat the COVID-19 infection. For instance, in August 2020, iBio,
Inc., a biotechnology innovator and biologics contract manufacturing
organization, announced that it has entered into an exclusive worldwide license
agreement with Planet Biotechnology Inc. for the development of Planet’s
COVID-19 therapeutic candidate, ACE2-Fc. ACE2-Fc is a recombinant protein
comprised of human angiotensin converting enzyme 2 (ACE2) fused to a human
immunoglobulin G Fc fragment (Fc). iBio is also developing multiple vaccine
platforms using its readily scalable FastPharming plant-based production system
to provide long-term immunity without the safety concerns presented by DNA- and
RNA-based vaccines.
The increasing number of pipeline
products, clinical trials, and collaborations and partnerships strategies
adopted by key players are the major factors, which are expected to drive
growth of the plant-based biologics market during the forecast period.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2394
The increasing number of
plant-based biologics products in the pipeline is expected to contribute
significantly to the plant-based biologics market growth. For instance,
Protalix Biotherapeutics’s, a global plant based biologics drug manufacturing
company have two major plant-based drug candidates in their pipeline – OPRX-106
is a plant cell-expressed recombinant human tumor necrosis factor receptor II
fused to an IgG1 Fc domain (TNFRII-Fc), for inhibiting TNF alpha. It is in
development for oral administration. OPRX-106 is used for the treatment of
ulcerative colitis and showed positive results from phase 2 clinical trial in
June 2018. Furthermore, Alidornase alfa (PRX-110) is a proprietary plant
cell-expressed recombinant form of human deoxyribonuclease I (DNase I) that the
company is developing to reduce the viscosity of sputum that accumulates in the
lungs of cystic fibrosis patients. The product is in phase 2 clinical trial.
Key players in the global
plant-based biologics market are focused on entering potential untapped markets
in various regions by expanding their manufacturing facilities. For instance,
in 2017, Ventria Bioscience Inc. expanded its biomanufacturing and laboratory
facilities to double Ventria’s production capacity of recombinant proteins, in
the Junction City, Kansas. The expanded facility involves addition of molecular
biology lab, greenhouses, process development and analytical lab, and
processing capacity. Furthermore, in 2017, PlantForm Corporation, in
partnership with Brazil-based Axis Biotec Brasil, launched a new joint venture,
which included a new facility consisting of a biopharmaceutical lab and pilot
production facility in Rio de Janeiro.
Browse 42 Market Data Tables and
34 Figures spread through 204 Pages and in-depth TOC on Global Plant-based
Biologics Market, by Product Type (Monoclonal Antibodies, Alpha Interferon,
Glucocerebrosidase, Vaccines, and Others), by Source Type (Carrot, Tobacco
Leaves, Rice Seeds, Alfalfa, and Others), by Disease Indication (Gaucher
Disease, Tooth Decay, Hepatitis, Lymphoma, and Others), and by Region (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -
Forecast to 2027"
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/plant-based-biologics-market-2394
The rising adoption of inorganic
growth strategies such as collaborations and partnerships by major companies is
expected to drive growth of the plant-based biologics market. For instance, in
August 2019, iBio, Inc., a global plant-based biopharmaceutical contract
development and cGMP manufacturing services company, announced that it has
expanded the scope of its business venture/collaboration with CC-Pharming Ltd.
by granting it an exclusive, royalty-bearing commercial license to iBio’s
bio-better rituximab (iBio Rituximab) product candidates for the territory of
China.
Key Takeaways of the Plant-based
Biologics Market:
The plant-based biologics market
is expected to exhibit a CAGR of 3.4% during the forecast period (2020-2027),
owing to the increasing number of product approvals and launches by key players
Among product type,
glucocerebrosidase segment is expected to hold major revenue share in 2027,
owing to the increasing product approval of plant-based biologics for human
use. For instance, in May 2012, Protalix BioTherapeutics and Pfizer Inc.
announced that the U.S. Food and Drug Administration (FDA) approved its
taliglucerase alfa for injection, as an enzyme replacement therapy (ERT) for
the long-term treatment of adult patients with a confirmed diagnosis of type 1
Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of
glucocerebrosidase (GCD) and is the company’s first approved drug product
developed using ProCellEx a platform to develop plant-based biologics.
Major players operating in the
plant-based biologics market include Leaf Expression Systems, Zea Biosciences,
Planet Biotechnology Inc., InVitria, PlantForm Corporation, IBIO, Inc., Mapp
Biopharmaceutical, Inc., Pfizer Inc., Ventria Bioscience Inc., Medicago Inc.,
Eleva GmbH, Kentucky Bioprocessing, LLC, Solarvest Bioenergy Inc., and Byondis
B.V.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2394
About Coherent
Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment